Navigation Links
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting

aseline International Prostate Symptom Score (IPSS) and uroflow values. Afterwards, 144 patients meeting the inclusion criteria were randomly allocated to one of five treatment groups with the following dosage regimens:

    - Placebo;

    - Ozarelix 5 mg on Day 1 + 5 mg on Day 15;

    - Ozarelix 10 mg on Day 1 +10 mg on Day 15;

    - Ozarelix 15 mg on Day 1 + 15 mg on Day 15; or

    - Ozarelix 20 mg on Day 1 only.

Patients were followed for 28 weeks. The primary efficacy endpoint was change in IPSS at week 12 compared to baseline. Secondary efficacy endpoints included changes in IPSS, Quality of Life (QoL), patients with >= 30% and >= 40% improvement in IPSS, uroflow values (Qmax), postvoid residual (PVR) urine volume and prostate volume. Safety analysis included changes in sexual function (IIEF-5), treatment of emergent adverse events (AEs), lab values (including testosterone (T), PSA) and vital signs. Mean age was 69.1 (range 52 - 85), IPSS 19.8, Qmax 9.7 mL/sec. and prostate size (cm(3)) 41.6 at baseline.

Results

The effects developed rapidly, with noticeable activity at four weeks from starting treatment, were maximal at 12-16 weeks, and persisted for the 6 month observation period. At week 12, all ozarelix-treated groups showed improvement with the greatest improvement in the 15 mg + 15 mg group. Change from baseline in IPSS was 8.6 (p<0.001); change from baseline in urine flow was 4.7 (p=0.002); T levels declined transiently and returned to baseline in most patients by 4 weeks and all patients by 6 weeks following dosing. Based on IIEF, there was no effect seen on erectile function.

Serious adverse events were reported in 4 patients on ozarelix (myocardial infarction, pneumonitis, hypotension, renal colic), but were not considered treatment related. No systemic allergic reactions were seen and the injections were well tolerated.

    Conclusions


    - Ozarelix was well tolerated;

    - Statistically sig
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... a press release on July 28, 2015, "Surviving ... Safety Launches Fundraising for Patient Safety." ... last sentence should read: "PPAHS is ... of Patients on Opioids. For more information on the ...
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... July 31, 2015 Magnaquest, ... video, data and cloud computing operators has signed ... pharma giant for Internet of Things (IoT) related ... offered on subscription model.      (Logo: ... is striving for business innovations to make healthcare ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... NEW YORK, Aug. 9, 2011 Reportlinker.com ... is available in its catalogue: ... and Investment Trends - Q2 2011 ... Medical Equipment Quarterly Deals Analysis: M&A and ...
... AUSTIN, Texas, Aug. 9, 2011 eCareSoft, Inc., a ... industry,s first Meaningful Use monitoring and tracking tool tied ... (MU) Scorecard™. "We quickly realized that visibility ... clients in achieving their targeted goals," stated Jorge Luis ...
Cached Medicine Technology:Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 2Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 3Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 4Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 5Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 6Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 7Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 8Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 9Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 10Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 11Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 12eCareSoft Drives Hospital Visibility to Stimulus Funds With Meaningful Use Scorecard™ 2
(Date:8/1/2015)... ... 2015 , ... “ reTXT ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... edit and delete any message including ones already sent. , While text messaging has ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin and blogs ... social media profiles to better connect with the public. The agency website at ... share insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide effortless ...
(Date:7/31/2015)... ... ... According to an article published July 2 on Healio, a ... consensus on the steps that need to be taken to successfully complete several plastic ... on a series of steps that each surgeon must complete for each procedure. Southern ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... unreimbursed loss of as little as $500 would have ... As unemployment rates continue to climb, one often ... to affordable insurance. In a national recent survey conducted ... nearly two-thirds of respondents admitted to living paycheck-to-paycheck "often" ...
... Danaher Corporation (NYSE: DHR ... has approved a regular quarterly dividend of $0.03 ... holders of record on June 26, 2009.Danaher Corporation ... Technologies, Industrial Technologies and Tools and Components ( ...
... Fiscal third quarter revenue from continuing operations increased $25 million, or ... , , , , ... , , , , , ... , , , , , ...
... (Nasdaq: ABAX ), a medical products company manufacturing ... operations officer, will present at the Bank of America and ... 2009 at 10:00 a.m. ET. The conference will be held ... invited to listen to a live audio webcast of the ...
... Ohio, May 7 STERIS Corporation (NYSE: STE ... a 38% increase in its quarterly dividend to $0.11 per ... to shareholders of record at the close of business on ... of STERIS Corporation is to provide a healthier today and ...
... Patient-Centered Primary Care Collaborative is the National ... ,Medical Home,WELLINGTON, Fla. May 7 The ... has joined the Executive Committee of the ... is a collaboration of major employers, consumer ...
Cached Medicine News:Health News:Affinion Group Survey Reveals That Underinsured Consumers Need Alternate Solutions in Light of Current Economic Climate 2Health News:Affinion Group Survey Reveals That Underinsured Consumers Need Alternate Solutions in Light of Current Economic Climate 3Health News:Perrigo Reports Record Third Quarter 2Health News:Perrigo Reports Record Third Quarter 3Health News:Perrigo Reports Record Third Quarter 4Health News:Perrigo Reports Record Third Quarter 5Health News:Perrigo Reports Record Third Quarter 6Health News:Perrigo Reports Record Third Quarter 7Health News:Perrigo Reports Record Third Quarter 8Health News:Perrigo Reports Record Third Quarter 9Health News:Perrigo Reports Record Third Quarter 10Health News:Perrigo Reports Record Third Quarter 11Health News:Perrigo Reports Record Third Quarter 12Health News:Perrigo Reports Record Third Quarter 13Health News:Perrigo Reports Record Third Quarter 14Health News:Perrigo Reports Record Third Quarter 15Health News:Perrigo Reports Record Third Quarter 16Health News:Perrigo Reports Record Third Quarter 17Health News:Perrigo Reports Record Third Quarter 18Health News:Perrigo Reports Record Third Quarter 19Health News:Perrigo Reports Record Third Quarter 20Health News:Perrigo Reports Record Third Quarter 21Health News:Perrigo Reports Record Third Quarter 22Health News:Abaxis, Inc. to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 3Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 2Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 3Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 4Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 5Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 6
... D15/810 diode laser is a versatile and ... soft tissue applications. With excellent hemostatic and ... flexible fiber optic delivery system that allows ... environments alike.,Compact and portable, the Ceralas D15/810 ...
... II is a monoclonal antibody based ... identification of Neisseria gonorrhoeae. The test ... run with no heating or pretreatment. ... viable or fresh cultures. GonoGen&trade II ...
The One-Step Gonorrhea Antigen Tests are qualitative immunoassays for detecting the Gonorrhea Antigen (NGH) in secretory products (swab)....
... thermal keratoplasty (LTK). This procedure was FDA ... reduction of hyperopia from +0.75 to +2.50 diopters ... to 0.75 diopters of astigmatism and refractive stability ... refractive surgery, LTK is not performed in an ...
Medicine Products: